Table 3. Efficacy data from CML-Study IV and SPIRIT.

	SPIRIT				CML-Study IV
	Imatinib 400 mg per day (n=159)	Imatinib 600 mg per day (n=160)	Imatinib 400 mg per day+cytarabine (n=158)	Imatinib 400 mg per day+PegIFNα-2a (n=159)	Imatinib 400 mg per day (n=306)	Imatinib 800 mg per day (n=328)	Imatinib 400 mg per day+IFNα (n=336)
Molecular response
6-Month major response			NA		9 (5–11)	18 (14–23)	8 (5–11)
12-Month major response	38 (30–46)	49 (41–57)	46 (38–54)	57 (49–65)	31 (27–36)	55 (49–60)	35 (29–39)
	Unadjusted P<0.001; adjusted P=0.005
12-Month superior response	14 (9–21)	17 (11–24)	15 (10–22)	30 (23–37)	NA
	Unadjusted P=0.001; adjusted P=0.001
18-Month major response	42 (34–50)	50 (42–58)	53 (45–61)	62 (54–69)	50 (44–56)	68 (62–73)	54 (48–59)
	Unadjusted P=0.004; adjusted P=0.003
18-Month superior response	18 (13–25)	22 (16–29)	19 (13–26)	35 (27–43)	NA
	Unadjusted P=0.002; adjusted P=0.001
24-Month major response	43 (35–50)	53 (45–60)	54 (46–62)	64 (56–71)	63 (57–68)	76 (71–81)	63 (57–68)
	Unadjusted P=0.006; adjusted P=0.003
24-Month superior response	21 (15–28)	26 (20–34)	26 (19–34)	38 (30–46)	NA
	Unadjusted P=0.001; adjusted P=0.007
24-Month undetectable residual disease	9 (5–14)	8 (4–13)	8 (4–13)	16 (12–24)	NA
	Unadjusted P=0.01; adjusted P=0.01
36-Month major response	NA				79 (74–84)	82 (76–86)	71 (65–75)
Complete cytogenetic response
6 Months	50 (42–58)	69 (61–76)	59 (51–67)	57 (49–65)	21 (16–26)	32 (26–37)	20 (15–24)
	Unadjusted P=0.007; adjusted P=0.005
12 Months	58 (50–66)	65 (57–72)	70 (62–77)	66 (58–73)	49 (43–54)	63 (56–68)	50 (44–55)
	Unadjusted P>0.05
18 Months	NA				66 (59–71)	69 (63–74)	75 (69–79)
24 Months	NA				74 (68–79)	82 (77–87)	77 (70–81)

Abbreviations: CML, chronic myeloid leukemia; NA, not available; PegIFNα, pegylated IFNα SPIRIT, STI571 Prospective Randomized Trial.